RE-BVS – Piemonte Repository

Sfoglia per AUTORE
CAGLIO A
Collezione AO Ordine Mauriziano

Items : 15

Withdrawal notice to . in The Lancet regional health. Europe / Lancet Reg Health Eur. 2024 Sep 2;44:101012. doi: 10.1016/j.lanepe.2024.101012. eCollection 2024 Sep

2024
AO Ordine Mauriziano

Iacovino ML; Celant S; Tomassini L; Arenare L; Caglio A; Canciello A; Salerno F; Olimpieri PP; Di Segni S; Sferrazza A; Piccirillo MC; Beretta GD; Pinto C; Blasi L; Cinieri S; Cavanna L; Di Maio M; Russo P; Perrone F;

Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study. in The Lancet regional health. Europe / Lancet Reg Health Eur. 2024 Apr 22;41:100912. doi: 10.1016/j.lanepe.2024.100912. eCollection 2024 Ju

2024
AO Ordine Mauriziano

Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912]. in The Lancet regional health. Europe / Lancet Reg Health Eur. 2024 Jun 24;42:100973. doi: 10.1016/j.lanepe.2024.100973. eCollection 2024 Ju

2024
AO Ordine Mauriziano

Iacovino ML; Celant S; Tomassini L; Arenare L; Caglio A; Canciello A; Salerno F; Olimpieri PP; Di Segni S; Sferrazza A; Piccirillo MC; Domenico Beretta G; Pinto C; Blasi L; Cinieri S; Cavanna L; Di Maio M; Russo P; Perrone F;

Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912]. in The Lancet regional health. Europe / Lancet Reg Health Eur. 2024 May 21;42:100940. doi: 10.1016/j.lanepe.2024.100940. eCollection 2024 Ju

2024
AO Ordine Mauriziano

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience. in Cancers / Cancers (Basel). 2023 Jul 15;15(14):3639. doi: 10.3390/cancers15143639.

2023
AO Ordine Mauriziano

Tuninetti V; Pace L; Ghisoni E; Quarà V; Arezzo F; Palicelli A; Mandato VD; Geuna E; Cormio G; Biglia N; Borsotti L; Gallo S; Ferrero A; Jacomuzzi E; Fuso L; Pezua Sanjinez JOS; Puppo A; Caglio A; Rognone C; Turinetto M; Scotto G; Di Maio M; Valabrega G;

Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2023 Aug;189:112920. doi: 10.1016/j.ejca.2023.05.008. Epub 2023 May 15.

2023
ASL Cuneo 2
AO Cuneo
ASL Torino 4
AO Ordine Mauriziano

Perrone F; Fabi A; Trastu F; Tuninetti V; Turco F; Reale ML; Paratore C; Mariniello A; Marandino L; Ghisoni E; Lombardi P; Gargiulo P; Gamba T; Di Liello R; Bungaro M; Caglio A; Di Maio M; Audisio M; Rossi A; Aimar G;

Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study. in BMJ oncology / BMJ Oncol. 2023 Mar 2;2(1):e000021. doi: 10.1136/bmjonc-2022-000021. eCollection 2023.

2023
AO Cuneo
AO Ordine Mauriziano

Turco F; Tuninetti V; Rossi A; Paratore C; Gargiulo P; Gamba T; Di Liello R; Caglio A; Bungaro M; Audisio M; Aimar G; Reale ML; Lombardi P; Mariniello A; Ghisoni E; Trastu F; Marandino L; Perrone F; Di Maio M;

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. in Journal for immunotherapy of cancer / J Immunother Cancer. 2022 Feb;10(2):e004374. doi: 10.1136/jitc-2021-004374.

2022
AO Ordine Mauriziano

Cortellini A; Ricciuti B; Vaz VR; Soldato D; Alessi JV; Dall'Olio FG; Banna GL; Muthuramalingam S; Chan S; Majem M; Piedra A; Lamberti G; Andrini E; Addeo A; Friedlaender A; Facchinetti F; Gorría T; Mezquita L; Hoton D; Valerie L; Nana FA; Artingstall J; Comins C; Di Maio M; Caglio A; Cave J; McKenzie H; Newsom-Davis T; Evans JS; et alii...

Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020. in ESMO open / ESMO Open. 2022 Dec;7(6):100593. doi: 10.1016/j.esmoop.2022.100593. Epub 2022 Oct 12.

2022
AO Ordine Mauriziano

Paratore C; Zichi C; Audisio M; Bungaro M; Caglio A; Di Liello R; Gamba T; Gargiulo P; Mariniello A; Reale ML; Perrone F; Di Maio M;

Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406]. in ESMO open / ESMO Open. 2022 Apr;7(2):100471. doi: 10.1016/j.esmoop.2022.100471. Epub 2022 Apr 1.

2022
AO Ordine Mauriziano

Cantini L; Mentrasti G; Lo Russo G; Signorelli D; Pasello G; Rijavec E; Russano M; Antonuzzo L; Rocco D; Giusti R; Adamo V; Genova C; Tuzi A; Morabito A; Gori S; La Verde N; Chiari R; Cortellini A; Cognigni V; Pecci F; Indini A; De Toma A; Zattarin E; Oresti S; Pizzutilo EG; Frega S; Erbetta E; Galletti A; Citarella F; et alii...

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. in ESMO open / ESMO Open. 2022 Apr;7(2):100406. doi: 10.1016/j.esmoop.2022.100406. Epub 2022 Feb 3.

2022
AO Ordine Mauriziano

Cantini L; Mentrasti G; Russo GL; Signorelli D; Pasello G; Rijavec E; Russano M; Antonuzzo L; Rocco D; Giusti R; Adamo V; Genova C; Tuzi A; Morabito A; Gori S; Verde N; Chiari R; Cortellini A; Cognigni V; Pecci F; Indini A; De Toma A; Zattarin E; Oresti S; Pizzutilo EG; Frega S; Erbetta E; Galletti A; Citarella F; et alii...

Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations. in Cancers / Cancers (Basel). 2021 May 17;13(10):2425. doi: 10.3390/cancers13102425.

2021
AO Ordine Mauriziano

Scagliotti GV; Bussolino F; Righi L; Di Maio M; Passiglia F; Listì A; Caglio A; Tabbò F; Sperone T; Reale ML; Bironzo P; Novello S;

Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;149:49-60. doi: 10.1016/j.ejca.2021.03.007. Epub 2021 Apr 3.

2021
AO Ordine Mauriziano

Perrone F; Caglio A; Gamba T; Bungaro M; Audisio M; Reale ML; Mariniello A; Gargiulo P; Zichi C; Paratore C; Di Maio M;

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. in Journal of clinical medicine / J Clin Med. 2021 Mar 2;10(5):1005. doi: 10.3390/jcm10051005.

2021
AO Ordine Mauriziano

Lenci E; Cantini L; Pecci F; Cognigni V; Agostinelli V; Mentrasti G; Lupi A; Ranallo N; Paoloni F; Rinaldi S; Nicolardi L; Caglio A; Aerts S; Cortellini A; Ficorella C; Chiari R; Di Maio M; Dingemans AC; Aerts JGJV; Berardi R; Lenci E; Cantini L; Pecci F; Cognigni V; Agostinelli V; Mentrasti G; Lupi A; Ranallo N; Paoloni F; et alii...

A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step? in Exploration of targeted anti-tumor therapy / Explor Target Antitumor Ther. 2021;2(5):448-464. doi: 10.37349/etat.2021.00056. Epub 2021 Oct 31.

2021
AO Ordine Mauriziano

Di Maio M; De Vita F; Gamba T; Caglio A; Sperti E; Marino D; Zichi C; Paratore C; Aimar G;